Age-Related Macular Degeneration

Blindness association applauds U.S. FDA's decision to approve Macugen

Published in Medical Letter on the CDC and FDA, January 23rd, 2005

Prevent Blindness America (PBA) applauded the U.S. Food and Drug Administration (FDA) for its decision to approve Macugen (pegaptanib sodium injection) for wet age-related macular degeneration (AMD), the leading cause of blindness in developed countries.

This approval marks a significant advance in the field of wet AMD because current treatment options are limited. Each year 200,000 Americans are diagnosed with wet AMD and this number is expected to increase dramatically with the aging of our population.

"Prevent Blindness America is very pleased with the FDA approval of Macugen, because for the first time all types of wet AMD can be treated, which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database